Jiangsu Atom Closes $45 Million Round for Global Phase III Gout Trial
January 05, 2022 at 05:38 AM EST
Jiangsu Atom Bioscience closed a $45 million Series C financing to support a global Phase III clinical trial of ABP-671, its lead small molecule drug for hyperuricemia and gout, along with preclinical/clinical development of other pipeline products. The company develops novel small molecule candidates for inflammatory and metabolic diseases such as chronic gout and non-alcoholic steatohepatitis. To date, Atom has raised a total of $87 million. The Series C was led by Xicheng Jinrui Equity Investment Fund and ShenZen GTJA Investment Group. More details.... Share this with colleagues: // //
